Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pediatr. 2010 Aug;157(2):310-315.e1. doi: 10.1016/j.jpeds.2010.02.040. Epub 2010 May 15.

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra.

Author information

  • 1IRCCS Burlo Garofolo, the Department of Reproductive and Developmental Sciences, University of Trieste, Italy.

Abstract

OBJECTIVE:

To evaluate the quality of life and long-term follow-up of patients enrolled in the Italian registry of cryopyrin-associated periodic syndromes (CAPS).

STUDY DESIGN:

Since 2004, 20 patients with CAPS were enrolled in a common registry from different Italian Centers of Pediatric Rheumatology; 14 patients were treated with Anakinra in an open fashion. Both treated and untreated patients were routinely followed according to standard of care. The Child Health Questionnaire (CHQ-PF 50) was used to assess the health-related quality of life.

RESULTS:

The mean duration of follow-up was 37.5 months. In all treated patients, a complete and persistent control of the inflammatory manifestations was observed with no further progression of the disease. At enrollment in the registry, patients showed a poorer health-related quality of life than healthy children in both physical and the psychosocial summary scores. Treatment was associated with a dramatic and sustained amelioration of a variety of measures of poor quality of life, particularly in those concerning the global health perception, bodily pain-discomfort, and other physical domains.

CONCLUSIONS:

Long-term IL-1 blockade produces a significant and persistent improvement in the clinical manifestations associated with the disease and on the overall quality of life.

Copyright (c) 2010. Published by Mosby, Inc.

PMID:
20472245
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk